Aquestive (AQST) news
Recent news
Eton Pharmaceuticals - To pay aQuestive royalties at mid-teens percentage rate on Libervant sales - SEC filing
Eton Pharmaceuticals has agreed to pay Aquestive Therapeutics royalties at a mid-teens percentage rate on future sales of Libervant, according to a recent SEC filing. The details of the agreement were disclosed in a regulatory submission, which outlines the financial terms of the partnership .…
AInvest Wire · 19h agoEton Pharmaceuticals - To pay Aquestive up to $47.50 mln in milestone payments - SEC filing
Eton Pharmaceuticals has agreed to pay Aquestive Therapeutics, Inc. up to $47.5 million in milestone payments, according to a recent SEC filing . The terms of the agreement outline specific financial obligations tied to the achievement of development and regulatory milestones related to one of…
AInvest Wire · 19h agoEton Pharma, Aquestive Thera enter exclusive license pact
AInvest Wire · 19h agoAquestive Therapeutics strengthens board of directors with appointment of Richard Daly
AInvest Wire · Sep 29, 2026Aquestive Therapeutics reports resubmission of NDA for anaphylm
Aquestive Therapeutics has announced the resubmission of its New Drug Application (NDA) for anaphylm, a treatment under development. The resubmission follows regulatory feedback and includes additional data and clarifications requested by the FDA. The company has not disclosed specific details…
AInvest Wire · Sep 17, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.